FDA classifies software that estimates a patient's odds of progressing to dementia
A final order published 5 November creates a class II category for prognostic software that weighs multiple clinical inputs to gauge the chance of progression from mild cognitive impairment — for adjunctive use only.
The Food and Drug Administration has created a device category for software that estimates how likely a patient with mild cognitive impairment is to progress toward dementia. In a final order published in the Federal Register on 5 November 2026, FDA classified the "prognostic assessment software of mild cognitive impairment" into class II, its middle regulatory tier, subject to special controls [s1].
What the device is
FDA defines the new generic type as a prescription-only device that combines information from multiple clinical data sources to produce an output indicating the likelihood that a patient diagnosed with mild cognitive impairment will progress to more severe forms of cognitive impairment, or develop dementia such as Alzheimer's disease dementia, within a specified period of time [s1]. The order draws a clear boundary around how such output may be used: the device "is intended for adjunctive use and not intended as a stand-alone diagnostic or prognostic tool" [s1].
The classification is codified at 21 CFR 882.1454, and the order is effective 5 November 2026 [s1]. As a prescription device, it is exempt from the requirement for adequate directions for use aimed at laypeople, provided the conditions for prescription-device labelling are met [s1].
Why the classification route matters
Any truly novel device is placed automatically into class III, the highest-risk category, which usually demands premarket approval. FDA can instead classify such a device through the "De Novo" process authorised under section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act [s1]. This order is the result of that process: FDA determined that special controls, together with general controls, provide a reasonable assurance of safety and effectiveness, and the classification was applicable as of 11 January 2024 [s1].
Once a device type sits in class II, later products of the same type can generally reach the market through the 510(k) premarket notification pathway rather than automatic class III review [s1]. FDA said the action will "enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens" [s1].
The special controls
The order names the principal risks as device failure or incorrect analysis, and requires measures to address them [s1]. Among the special controls, data from premarket clinical performance validation testing and from postmarket surveillance, acquired under anticipated conditions of use, must demonstrate that the device performs as intended when used to analyse patient data [s1]. A device must comply with the named special controls to fall within the class II classification and avoid automatic placement in class III [s1]. The combination of validation evidence, labelling and the adjunctive-use limitation is what FDA relies on to keep the prognostic output within safe bounds.
What mild cognitive impairment is
Mild cognitive impairment describes a measurable decline in memory or thinking that is greater than expected for a person's age but not severe enough to interfere substantially with daily life. It sits between normal ageing and dementia, and its course is genuinely uncertain: some people with the condition progress to dementia, some remain stable, and some improve. That uncertainty is the clinical problem the software addresses, by turning several clinical inputs into an estimated probability of progression within a stated window [s1]. It is also why the stakes of a wrong estimate are high, which is the reason FDA tied the category to validation evidence rather than leaving it in the uncontrolled class III default [s1].
Why the "adjunctive" limit is central
Prognosis in mild cognitive impairment is uncertain by nature. Not everyone with the condition progresses to dementia, and timelines vary widely. By defining the device as adjunctive and not a stand-alone tool, FDA's order keeps the clinician in charge of interpreting any estimate the software produces [s1]. The device offers a probability to inform a clinical picture, not a verdict a patient or doctor is meant to act on alone. The order's requirement for postmarket surveillance data, acquired under anticipated conditions of use, means the evidence does not stop at approval but continues as the software is used in practice [s1].
What is settled
What the order fixes is concrete. A dated final order now exists, the device type is class II, the classification lives at 21 CFR 882.1454, the special controls are codified, and the order took effect on 5 November 2026 [s1]. What it does not do is approve any specific product for sale, validate any particular algorithm's accuracy, or change how clinicians should counsel patients about their risk. The category sets the regulatory tier and the evidence any such software must meet; the output, by the device's own definition, is an aid to judgement rather than a diagnosis [s1].
Sources
- Medical Devices; Neurological Devices; Classification of the Prognostic Assessment Software of Mild Cognitive Impairment — U.S. Food and Drug Administration / Federal Register , November 5, 2026
More on
FDA sets a class II path for AI systems that help read Pap-test slides
A final order published 5 November creates a device category for digital cervical cytology imaging systems with AI, letting future versions clear through the 510(k) route instead of the strictest class III review.
FDA creates a class II category for wearable bone-vibration devices
A final order published 5 November classifies wearable devices that apply targeted mechanical vibration to the skeleton to reduce loss of bone strength or density, setting the evidence such products must meet.
Chronic illness tracks with whether people vote — and the direction is not uniform
A US survey and a Finnish register study agree that health shapes turnout, but not in one direction: diabetes was linked to higher voting, dementia to markedly lower. Both are associations, not proof.
FDA creates a class II category for at-home STI test kits read in the lab
A final order published 9 October classifies systems that let people collect their own specimens for non-viral STI testing as class II, moving them out of the automatic class III that demands premarket approval.